ATE452894T1 - Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen - Google Patents

Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen

Info

Publication number
ATE452894T1
ATE452894T1 AT06758390T AT06758390T ATE452894T1 AT E452894 T1 ATE452894 T1 AT E452894T1 AT 06758390 T AT06758390 T AT 06758390T AT 06758390 T AT06758390 T AT 06758390T AT E452894 T1 ATE452894 T1 AT E452894T1
Authority
AT
Austria
Prior art keywords
methylphenylüaminoü
füä1
carbonylü
cyclopropylamino
carboxamide
Prior art date
Application number
AT06758390T
Other languages
English (en)
Inventor
Soonjin Kim
Mary F Malley
Zhongping Shi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE452894T1 publication Critical patent/ATE452894T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT06758390T 2005-04-18 2006-04-18 Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen ATE452894T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67225505P 2005-04-18 2005-04-18
PCT/US2006/014504 WO2006113682A1 (en) 2005-04-18 2006-04-18 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein

Publications (1)

Publication Number Publication Date
ATE452894T1 true ATE452894T1 (de) 2010-01-15

Family

ID=36693144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06758390T ATE452894T1 (de) 2005-04-18 2006-04-18 Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen

Country Status (12)

Country Link
US (3) US20060235020A1 (de)
EP (1) EP1874778B1 (de)
JP (1) JP5047160B2 (de)
CN (1) CN101198610B (de)
AR (1) AR053586A1 (de)
AT (1) ATE452894T1 (de)
DE (1) DE602006011295D1 (de)
ES (1) ES2336363T3 (de)
NO (1) NO20075095L (de)
PE (1) PE20061429A1 (de)
TW (1) TW200716126A (de)
WO (1) WO2006113682A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
WO2012024489A2 (en) * 2010-08-18 2012-02-23 Emory University Compounds and compositions for ossification and methods related thereto
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
CN104003990B (zh) * 2013-02-21 2017-09-15 江苏先声药业有限公司 杂环胺类Hedgehog信号通路抑制剂
CN106068619B (zh) * 2014-01-24 2019-11-19 华为技术有限公司 用于进行交叉极化干扰抑制的方法和设备
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
GB2533833B (en) * 2015-06-22 2016-12-14 Univ Bristol Wireless ultrasound sensor with two induction coils
CN105651804B (zh) * 2016-03-11 2017-05-17 山西大学 一种慢性萎缩性胃炎大鼠模型的评价方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
WO2020209868A1 (en) * 2019-04-12 2020-10-15 Bruker Axs, Inc. A system and method for diffraction-based structure determination with simultaneous processing modules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) * 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6251914B1 (en) * 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors

Also Published As

Publication number Publication date
JP2008538373A (ja) 2008-10-23
DE602006011295D1 (de) 2010-02-04
EP1874778A1 (de) 2008-01-09
CN101198610A (zh) 2008-06-11
JP5047160B2 (ja) 2012-10-10
CN101198610B (zh) 2012-06-13
PE20061429A1 (es) 2006-12-17
TW200716126A (en) 2007-05-01
ES2336363T3 (es) 2010-04-12
US20120108594A1 (en) 2012-05-03
NO20075095L (no) 2007-11-15
US20090312331A1 (en) 2009-12-17
US20060235020A1 (en) 2006-10-19
EP1874778B1 (de) 2009-12-23
WO2006113682A1 (en) 2006-10-26
AR053586A1 (es) 2007-05-09

Similar Documents

Publication Publication Date Title
ATE486844T1 (de) Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
EP1877175A4 (de) Vorrichtung und verfahren zur herstellung von radiopharmazeutika
DE112005002138A5 (de) Verfahren und Vorrichtung zur Herstellung von Formkörpern aus Cellulose
DE60322537D1 (de) Verfahren zur herstellung von kohlenstoffnanoröhren
DE602005026987D1 (de) Verfahren zur herstellung von 1,2-dichlorethan
DE602004028370D1 (de) Verfahren zur bilderzeugung, bilderzeugungsgerät, zwischenelement, und verfahren zur modifizierung der oberfläche des zwischenelementes
DE602006019413D1 (de) Verfahren und vorrichtung zur herstellung von elektrogesponnenen fasern und damit hergestellte fasern
DE60328421D1 (de) Verfahren zur herstellung von super-hydrophoben oberflächen, daraus hergestellte oberflächen und deren verwendung
DE60232605D1 (de) Verfahren zur herstellung von durchblasgetrocknetem tissueprodukt mit abdampfrückgewinnung
ATE462806T1 (de) Verfahren zur herstellung von titan
ATE452894T1 (de) Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen
DE602006018429D1 (de) Verfahren zur herstellung von verschlüssen
DE60304119D1 (de) Verfahren zur Herstellung von dünnwandigen gleichartigen Gitterstrukturen
DE03713610T1 (de) Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
DE602004005137D1 (de) Verfahren zur Herstellung von Nanopartikeln
ATE486841T1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE517898T1 (de) Verfahren zur herstellung von triazolsubstituierten azaindoloxoessigsäurepiperazinderivaten und dabei hergestellte neue salzformen
DE60127675D1 (de) Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben
ATE430140T1 (de) Verfahren zur herstellung von ä1,4,5ü- oxadiazepinderivaten
ATE453619T1 (de) Verfahren zur herstellung von hydroperoxiden
DE602006013572D1 (de) Resistzusammensetzung und Verfahren zur Herstellung von Mustern
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties